Литература
1. Global Strategy for the Diagnosis. Management and Prevention of COPD. [Internet]. Global Initiative for Chronic Obstructive Lung Disease (GOLD); 2018. http://goldcopd.org/.
2. Клинические рекомендации "Хроническая обструктивная болезнь легких" (утв. Минздравом России). [Электронный ресурс]. Российское респираторное общество; 2018.
3. Сахарова Г.М., Антонов Н.С., Михайлова Ю.В., Передельская М.Ю. Рекомендации по оказанию медицинской помощи при отказе от табакокурения пациентам с хронической обструктивной болезнью легких и бронхообструктивными нарушениями. Пульмонология. 2019;29 (3):327-333. doi:10.18093/0869-0189-2019-29-3-327-333.
4. Wells AD, Woods A, Hilleman DE, Malesker MA. Alpha-1 Antitrypsin Replacement in Patients With COPD. P T. 2019; 44 (7): 412-415.
5. Trinkmann F, Saur J, Borggrefe M, Akin I. Cardiovascular Comorbidities in Chronic Obstructive Pulmonary Disease (COPD)—Current Considerations for Clinical Practice. J Clin Med. 2019. 8(1): 69. doi: 10.3390/jcm8010069.
6. Pavasini R, d'Ascenzo F, Campo G, Biscaglia S, Ferri A, Contoli M et al. Cardiac troponin elevation predicts all-cause mortality in patients with acute exacerbation of chronic obstructive pulmonary disease: Systematic review and meta-analysis. Int J Cardiol. 2015; 191: 87-93. doi: 10.1016/j.ijcard.2015.05.006.
7. Wheelock CE, Goss VM, Balgoma D, Nicholas B, Brandsma J, Skipp PJ et al. Application of ’omics technologies to biomarker discovery in inflammatory lung diseases. Eur Respir J. 2013; 42(3): 802-825. doi: 10.1183/09031936.00078812.
8. Agusti A, Mac Nee W. The COPD control panel: towards personalised medicine in COPD. Thorax. 2013; 68: 687–690. doi:10.1136/thoraxjnl-2012-202772.
9. Малявин А.Г., Мартынов А.И., Ардашева Т.В., Бабак С.Л., Беленков Ю.Н., Бойцов С.А. и др. Диагностика и лечение пациентов с хронической обструктивной болезнью легких и хронической сердечной недостаточностью. Национальные Клинические Рекомендации 2018, Российское Научное Медицинское Общество Терапевтов (РНМОТ). Терапия. 2019; 5 (31): 59-100. doi: 10.18093/0869-0189-2016-26-1-38-45.
10. Aisanov Z.R., Avdeev S.N., Arkhipov V.V., Belevsky A.S., Leshchenko I.V., Ovcharenko S.I. et al. National clinical guidelines on diagnosis and treatment of chronic obstructive pulmonary disease: a clinical decision-making algorithm. Russian Pulmonology 2017; 27(1):13-20. In Russian. doi: 10.18093/0869-0189-2017-27-1-13-20.
11. Beeh KM, Burgel PR, Franssen FME, Lopez-Campos JL, Loukides S, Hurst JR et al. How Do Dual Long-Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease? Am J Respir Crit Care Med. 2017; 196(2):139-149. doi: 10.1164/rccm.201609-1794CI.
12. Rogliani P, Calzetta L, Braido F, Cazzola M, Clini E, Pelaia G. LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review. Int J COPD. 2018; 13: 3115–3130. doi: 10.2147/COPD.S170606.
13. Wedzicha JA, Decramer M, Ficker JH, Niewoehner DE, Sandstrцm T, Taylor AF et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, doubleblind, parallel-group study. Respir Med. 2013; 1(3):199–209. doi: 10.1016/S2213-2600(13)70052-3.
14. Calverley PM, Anzueto AR, Carter K, Grцnke L, Hallmann C, Jenkins C et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. Respir Med. 2018; 6 (5): 337-344. doi. 10.1016/S2213-2600(18)30102-4
15. Soler-Cataluсa JJ, Alcazar-Navarrete B, Miravitlles M. The concept of control of COPD in clinical practice. Int J COPD. 2014; 9:1397–1405. doi: 10.2147/COPD.S71370.
16. Sharafkhaneh A, Altan AE, Colice GL, Hanania NA, Donohue JF, Kurlander JL et al. A simple rule to identify patients with chronic obstructive pulmonary disease who may need treatment reevaluation. Respir Med. 2014; 108(9): 1310-1320. doi: 10.1016/j.rmed.2014.07.002.
17. Iannella H, Luna C, Waterer G. Inhaled corticosteroids and the increased risk of pneumonia: what’s new? A 2015 updated review. Ther Adv Respir Dis. 2016; 10(3): 235–255. doi: 10.1177/1753465816630208.
18. Barr RG, Bluemke DA, Ahmed FS, Carr JJ, Enright PL, Hoffman EA et al. Percent Emphysema, Airflow Obstruction, and Impaired Left Ventricular Filling. N Engl J Med. 2010; 362(3): 217-227 doi: 10.1056/NEJMoa0808836.
19. Hohlfeld JM, Vogel-Claussen J, Biller H, Berliner D, Berschneider K, Tillmann HC et al. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial.